Loxo '292 And Cancer Drug Development Today: So Much Promise, So Many Questions

 
• By Jessica Merrill
  
Generate a summary of this article
Listen to this article
Beta

Loxo data on the RET inhibitor LOXO-292 impressed at ASCO, so much so the company is looking to talk to regulators about the results after only a single-arm Phase I trial – but it's not a silver bullet as a tissue-agnostic treatment. Data on a separate target, PI3K, underwhelmed in breast cancer. Tissue of origin remains important, though the reasons why are not entirely understood. 

chess

Loxo Oncology Inc.'s highly selective RET inhibitor LOXO-292 stood out at the American Society of Clinical Oncology annual meeting as one example of where cancer drug development is going – toward cancer treatment based on the molecular underpinnings of disease rather than tissue of origin. But while Loxo presented encouraging data as a tissue agnostic approach for select patients, the importance of tissue of origin can't be ignored. Data presented on a different drug, Roche's PI3K inhibitor taselisib, from a basket trial funded by the National Cancer Institute, disappointed, highlighting the persistent challenges.

The drug industry is increasingly moving the precision medicine goalpost forward, from chimeric antigen receptor T-cell (CAR-T) therapy to next-generation...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By Xu Hu

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By Xu Hu

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D